DNLI News and Press, Denali Therapeutics Inc. From 11/18/20

Often, the best investments are the ones most of the market isn't paying attention to. With all eyes focused on coronavirus stocks, it may be a good time for investors to look at the possibilities for progress on other diseases that have plagued us for a lot longer. Alzheimer's, for exa...

Denali Therapeutics (DNLI) announces successful biomarker proof-of-concept for its Transport Vehicle ((TV)) technology in a Phase 1/2 clinical trial evaluating ETV-IDS (DNL310) for the potential treatment of mucopolysaccharidosis type II ((MPSII)), a rare inherited lysosomal storage disorder ...

After four weekly intravenous doses of DNL310, a 76% mean reduction in CSF GAG levels (heparan sulfate) from baseline was observed, with normal healthy levels being achieved in four of five patients Based on Cohort A safety data review, an independent data monitoring committee recomme...

Denali Therapeutics (DNLI): Q3 GAAP EPS of -$0.54.Revenue of $9.39M (-31.0% Y/Y)Press Release For further details see: Denali Therapeutics reports Q3 results

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial r...

Biogen has embraced Ionis antisense technology for neurology targets. A new Gene Therapy Accelerator Unit was formed last year and has facilitated the creation of new business units and collaborations in 2020. The stock has been in a holding pattern for six years. Once pipeline pr...

As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...

Proprietary and differentiated Transport Vehicle (TV) technology shows potential to solve the BBB challenge by delivering biotherapeutics to the brain New preclinical data support the potential for systemic administration of ETV:IDS (DNL310) to treat the neurological pathology of Hunt...

Germany-based Secarna Pharmaceuticals has signed a research and option agreement with Denali Therapeutics ([[DNLI]] -0.5%), under which, the companies will leverage former's LNAplus antisense oligonucleotide discovery platform and later's blood-brain barrier against neurodegenerative dis...

Sarepta has a diversified portfolio of 43 programs including 27 gene therapy and 14 RNA programs. The pipeline is spread between discovery (21) and commercial (2) medicines. The current valuation for Sarepta is comparable to the group of 6 gene therapy companies acquired between 2017 ...